YNL339W-A Antibody

What is YNL339W-A protein and what organism systems is it found in?

YNL339W-A is classified as a putative uncharacterized protein found in Saccharomyces cerevisiae (strain 204508/S288c) or baker's yeast. As an uncharacterized protein, its precise biological function remains to be fully elucidated, making it an important target for fundamental yeast biology research. The protein is believed to be membrane-associated based on structural predictions and comparative analyses with related proteins. Current experimental approaches to characterize its function include molecular genetic techniques such as gene knockout studies, localization experiments using tagged protein variants, and comparative functional genomics with other yeast strains .

What are the standard methodological considerations for using YNL339W-A antibodies in Western blotting?

When employing YNL339W-A antibodies for Western blot applications, researchers should implement the following methodological approach:

• Sample preparation: Optimize protein extraction from yeast cells using appropriate lysis buffers that preserve membrane protein integrity

• Gel selection: Use gradient gels (10-15% polyacrylamide) for optimal resolution

• Transfer conditions: Employ wet transfer methods with methanol-containing buffers for 60-90 minutes

• Blocking: Use 5% non-fat dry milk or BSA in TBST for 1-2 hours at room temperature

• Primary antibody incubation: Dilute rabbit anti-YNL339W-A polyclonal antibody at 1:500-1:2000 in blocking buffer

• Detection: Implement HRP-conjugated anti-rabbit secondary antibodies and enhanced chemiluminescence for visualization

Expected results should include a specific band corresponding to the predicted molecular weight of YNL339W-A. Validation should include appropriate negative controls to ensure antibody specificity .

How do experimental applications differ between YNL339W-A and YNL339W-B antibodies?

Methodologically, while both antibodies share similar applications, researchers should note that YNL339W-B belongs to the UPF0479 family with predicted membrane localization, which may necessitate different extraction and experimental conditions compared to YNL339W-A .

What are the optimal storage and handling protocols for YNL339W-A antibodies?

To maintain antibody functionality and prevent degradation, follow these research-validated handling protocols:

• Long-term storage: Store at -20°C to -70°C in small aliquots to prevent repeated freeze-thaw cycles

• Working aliquots: Store at 2-8°C for up to 1 month under sterile conditions after reconstitution

• Reconstitution: Use sterile PBS or the recommended buffer at the concentration specified by the manufacturer

• Freeze-thaw cycles: Limit to fewer than 5 cycles to preserve antibody activity

• Contamination prevention: Use sterile pipette tips and aseptic handling techniques

• Transport: Ship with ice packs to maintain cold chain integrity

For extended storage (>6 months), maintain at -20°C to -70°C in buffer containing cryopreservatives such as 50% glycerol. Proper storage and handling significantly impact experimental reproducibility and antibody performance in sensitive applications like ELISA and Western blotting .

What controls should be included when validating YNL339W-A antibody specificity?

When validating YNL339W-A antibody specificity, implement this comprehensive control strategy:

• Positive controls:

  • Recombinant YNL339W-A protein (≥85% purity as determined by SDS-PAGE)

  • Wild-type S. cerevisiae lysates with confirmed YNL339W-A expression

• Negative controls:

  • Pre-immune serum to establish baseline reactivity

  • YNL339W-A knockout/knockdown yeast strains

  • Non-target yeast species to assess cross-species reactivity

• Specificity controls:

  • Competitive inhibition with purified recombinant YNL339W-A

  • Testing against related proteins (particularly YNL339W-B) to assess cross-reactivity

  • Secondary antibody-only controls to detect non-specific binding

Systematically implementing these controls enables researchers to confidently attribute experimental signals to specific YNL339W-A detection rather than non-specific interactions or technical artifacts .

What approaches can resolve contradictory experimental results when using YNL339W-A antibodies?

When faced with contradictory results using YNL339W-A antibodies, implement this systematic troubleshooting methodology:

• Antibody validation reassessment:

  • Perform epitope mapping to identify the specific binding region

  • Verify antibody lot-to-lot consistency through comparative Western blots

  • Implement orthogonal detection methods (e.g., mass spectrometry)

• Experimental condition optimization:

  • Conduct buffer compatibility analysis across different extraction methods

  • Test multiple fixation protocols for immunocytochemistry applications

  • Establish optimal antigen retrieval methods for embedded samples

• Sample preparation variables:

  • Evaluate protein denaturation effects on epitope accessibility

  • Assess post-translational modification interference with antibody binding

  • Compare results across different growth phases and stress conditions

• Advanced controls:

  • Implement CRISPR-edited yeast strains with epitope-tagged YNL339W-A

  • Use computational prediction models to identify potential cross-reactive epitopes

  • Employ multiplexed detection with differently-labeled antibodies targeting distinct epitopes

This comprehensive approach can identify the source of experimental discrepancies, whether they stem from antibody limitations, technical variables, or biological complexity of the YNL339W-A protein system .

How can researchers design experiments to differentiate between YNL339W-A and related protein detection?

To achieve high-specificity differentiation between YNL339W-A and related proteins (particularly YNL339W-B), implement this experimental design strategy:

• Epitope-specific approach:

  • Utilize antibodies targeting non-conserved regions between related proteins

  • Implement competitive binding assays with differential peptide inhibition

  • Design immunoprecipitation experiments with sequential epitope detection

• Expression system manipulation:

  • Generate differential knockout models expressing only YNL339W-A or related proteins

  • Create epitope-tagged proteins with distinguishable molecular weights

  • Implement inducible expression systems with temporal separation

• Advanced detection methodology:

  • Employ super-resolution microscopy with dual-labeled antibodies

  • Utilize proximity ligation assays for protein-specific interaction mapping

  • Implement mass spectrometry following immunoprecipitation for definitive identification

• Analytical validation:

  • Construct calibration curves using recombinant proteins of known concentration

  • Develop computational models to predict cross-reactivity potential

  • Implement machine learning algorithms for signal deconvolution in complex samples

This comprehensive strategy enables precise discrimination between YNL339W-A and related proteins, particularly in experimental systems where both may be expressed simultaneously .

What are the current biophysical models for antibody-epitope interactions with yeast membrane proteins like YNL339W-A?

Current biophysical models for antibody-epitope interactions with yeast membrane proteins like YNL339W-A integrate multiple parameters for predicting binding specificity and optimization:

• Binding mode characterization:

  • Multiple binding modes can be identified through phage display experiments

  • Each binding mode associates with a distinct ligand (epitope)

  • Binding energetics can be mathematically expressed through biophysically interpretable models

  • These models can disentangle different contributions to binding from a single experiment

• Computational predictive frameworks:

  • Shallow dense neural networks can parametrize binding energetics for each mode

  • Optimization algorithms enable prediction of antibody variants with custom specificity profiles

  • Sequence-based prediction identifies antibodies with either high specificity or cross-reactivity

• Experimental validation approaches:

  • Systematic variation of CDR3 regions (particularly positions within a four amino acid sequence)

  • Selection against complex targets with related epitopes

  • High-throughput sequencing to monitor antibody population evolution

• Design implications:

  • Models enable the computational design of antibodies with predetermined specificity profiles

  • Generation of novel antibody sequences not present in initial libraries

  • Creation of either highly specific antibodies or cross-specific variants depending on research needs

These advanced biophysical models have particular relevance for membrane proteins like YNL339W-A where epitope accessibility and specificity present significant challenges for antibody development and application .

What methodological approaches best characterize post-translational modifications of YNL339W-A using antibody-based detection?

To effectively characterize post-translational modifications (PTMs) of YNL339W-A, implement this comprehensive methodological framework:

• Modification-specific antibody approach:

  • Develop antibodies targeting predicted PTM sites based on bioinformatic analysis

  • Implement validation using synthetic peptides with and without modifications

  • Establish signal calibration using recombinant proteins with controlled modification states

• Enzymatic treatment strategy:

  • Compare antibody reactivity before and after phosphatase treatment for phosphorylation

  • Assess glycosylation through differential detection after glycosidase treatment

  • Analyze ubiquitination through proteasome inhibition and comparative detection

• Advanced analytical techniques:

  • Combine immunoprecipitation with mass spectrometry for PTM site identification

  • Implement 2D gel electrophoresis to separate modified protein variants

  • Utilize Phos-tag™ technology for phosphorylation-dependent mobility shift detection

• Integrated validation approach:

  • Correlate PTM detection with functional assays under varying cellular conditions

  • Perform site-directed mutagenesis of putative modification sites

  • Implement temporal analysis during cell cycle progression or stress response

This methodological framework enables comprehensive characterization of YNL339W-A post-translational modifications, providing insights into regulatory mechanisms governing this putative membrane protein's function .

How can researchers implement advanced antibody engineering for improved YNL339W-A detection in complex experimental systems?

To overcome current limitations in YNL339W-A detection through advanced antibody engineering, implement this research-based methodology:

• Epitope-focused optimization:

  • Implement phage display selection against specific YNL339W-A domains

  • Utilize biophysics-informed modeling to predict optimal binding regions

  • Develop antibody variants with customized specificity profiles through computational design

  • Test variants not present in initial libraries to achieve novel binding properties

• Antibody format diversification:

  • Generate single-domain antibodies for improved access to membrane protein epitopes

  • Develop bispecific antibodies targeting multiple YNL339W-A epitopes simultaneously

  • Create antibody fragments with enhanced permeability for intracellular applications

  • Implement site-specific conjugation for controlled labeling orientation

• Selection strategy advancement:

  • Conduct selection experiments against combinations of related ligands

  • Perform selections with pre-depletion steps to remove cross-reactive antibodies

  • Monitor library composition through high-throughput sequencing at each selection step

  • Implement machine learning models to identify optimal antibody candidates based on sequence features

• Validation in complex systems:

  • Test engineered antibodies in native membrane environments

  • Compare detection efficiency across different yeast strains and growth conditions

  • Implement orthogonal detection methods for cross-validation

  • Assess performance in mixed protein samples with potential cross-reactive targets

This comprehensive engineering approach can significantly improve YNL339W-A detection specificity and sensitivity, especially in challenging experimental contexts where current antibody limitations restrict detailed characterization .

What quantitative parameters should be established when validating YNL339W-A antibodies for research applications?

To ensure robust experimental outcomes when working with YNL339W-A antibodies, researchers should establish these quantitative validation parameters:

These quantitative parameters establish a rigorous foundation for antibody validation, ensuring experimental reproducibility and reliable data interpretation across different research contexts .

What are the emerging techniques for studying YNL339W-A protein interactions in yeast membrane systems?

Current cutting-edge methodologies for investigating YNL339W-A protein interactions within native membrane environments include:

• Proximity-based interaction mapping:

  • BioID-based proximity labeling with YNL339W-A fusion proteins

  • APEX2-mediated biotinylation of proximal proteins

  • Split-protein complementation assays in membrane contexts

  • FRET/BRET-based interaction detection with fluorescently-tagged binding partners

• Advanced microscopy approaches:

  • Super-resolution imaging of YNL339W-A localization patterns

  • Single-molecule tracking to assess membrane dynamics

  • Correlative light-electron microscopy for structural context

  • Lattice light-sheet microscopy for long-term monitoring with reduced phototoxicity

• Membrane-specific biochemical methods:

  • Nanodiscs for reconstitution of membrane protein complexes

  • Crosslinking mass spectrometry adapted for membrane proteins

  • Hydrogen-deuterium exchange mass spectrometry for conformational analysis

  • Native mass spectrometry of intact membrane protein complexes

• Integrated computational modeling:

  • Molecular dynamics simulations of YNL339W-A in lipid bilayers

  • Coarse-grained modeling of protein-protein interaction networks

  • Machine learning approaches for interaction prediction from sequence data

  • Systems biology frameworks integrating multi-omics data

These emerging techniques collectively offer unprecedented insights into YNL339W-A function within membrane contexts, particularly important for this putative membrane protein whose precise function remains to be fully characterized .

How do environmental and experimental conditions affect YNL339W-A antibody performance?

Researchers should consider these critical environmental and experimental variables that significantly impact YNL339W-A antibody performance:

Methodical optimization of these parameters is essential for reproducible experimental outcomes, particularly for membrane proteins like YNL339W-A where sample preparation significantly impacts antibody accessibility to target epitopes .

What are the current hypotheses regarding YNL339W-A function based on antibody-enabled research?

While YNL339W-A remains classified as a putative uncharacterized protein, antibody-based studies have contributed to several emerging hypotheses about its potential functions:

• Membrane organization role:

  • Localization patterns suggest potential involvement in membrane domain organization

  • Possible interaction with lipid rafts or specialized membrane compartments

  • Structural similarities to membrane scaffolding proteins in related organisms

  • Potential role in maintaining membrane integrity during stress conditions

• Protein transport function:

  • Co-localization with secretory pathway components

  • Temporal expression patterns correlating with protein trafficking events

  • Structural domains consistent with membrane transport machinery

  • Phenotypic effects on secreted protein profiles when expression is altered

• Stress response involvement:

  • Expression upregulation during specific cellular stress conditions

  • Co-immunoprecipitation with known stress response mediators

  • Structural features suggesting post-translational modification under stress

  • Localization changes correlated with cellular adaptation to environmental challenges

• Potential redundancy with YNL339W-B:

  • Shared structural features suggesting overlapping functions

  • Differential expression patterns indicating condition-specific roles

  • Compensatory upregulation observed in knockout models

  • Evolutionary conservation patterns suggesting functional importance

These hypotheses represent active areas of investigation, with antibody-based detection methods providing critical tools for elucidating YNL339W-A's biological function through localization, interaction, and expression studies .

How can researchers integrate antibody-based detection with genetic approaches to study YNL339W-A?

A comprehensive strategy for integrating antibody-based detection with genetic approaches involves this methodological framework:

• CRISPR-based genome editing:

  • Generate epitope-tagged YNL339W-A at endogenous loci for natural expression levels

  • Create conditional expression systems through promoter replacement

  • Implement domain-specific mutations to correlate structure with function

  • Generate clean knockouts for loss-of-function validation

• Antibody-enabled phenotypic analysis:

  • Track protein localization changes across genetic backgrounds

  • Quantify expression levels in response to genetic perturbations

  • Identify genetic interaction networks through synthetic genetic array analysis

  • Correlate protein-level changes with transcriptional alterations

• Functional genomics integration:

  • Combine immunoprecipitation with RNA-seq for RNA-binding potential

  • Implement ChIP-seq if DNA-interaction is suspected

  • Utilize proximity labeling with genetic variant libraries

  • Correlate proteomics data with genetic screen outcomes

• Evolutionary approaches:

  • Compare YNL339W-A structure and function across yeast species

  • Identify conserved interaction partners through comparative immunoprecipitation

  • Correlate sequence conservation with antibody epitope accessibility

  • Reconstruct functional evolution through heterologous expression systems